Time to Maximal Response of Trastuzumab Deruxtecan in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (TRACE)
In a multicenter retrospective study of 93 patients with HER2-positive metastatic breast cancer, Trastuzumab Deruxtecan achieved maximal tumor shrinkage at a median of 4.57 months, with minimal additional tumor burden reduction observed beyond 18 weeks, suggesting that treatment duration may be optimized by considering this timeframe for induction strategies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body is a bustling city, and for some people, a specific type of troublemaker called "HER2-positive breast cancer" has set up shop. These troublemakers are aggressive, but scientists have a super-weapon called Trastuzumab Deruxtecan (or T-DXd for short). This weapon is like a high-tech missile that locks onto the troublemakers and delivers a powerful payload to shrink them down.
For a long time, doctors have been asking a tricky question: How long do we need to fire these missiles before the city is as safe as it's ever going to be?
This is where a team of researchers from Japan stepped in with a study called TRACE. They looked back at the records of 93 real patients (out of 125 who started treatment) to see exactly when the "missiles" stopped shrinking the troublemakers and just started keeping them in check.
The Big Discovery: The "Sweet Spot"
The researchers found that, on average, it takes 4.57 months (about six cycles of treatment) for the tumors to reach their smallest size. Think of it like a game of Whac-A-Mole. You hit the moles, and they go down. But after about four and a half months, the moles stop going any lower. They hit a floor.
The study suggests that once you hit that 4.57-month mark, keeping the heavy missiles firing doesn't usually make the city any safer. In fact, if you look at what happened after 18 weeks (about four months), the average change in tumor size was a tiny −2.7%. That's barely a whisper of extra shrinking. It's like trying to squeeze a sponge that's already completely dry; you're just wasting your effort.
What This Means for Treatment Plans
Because the tumors stop shrinking significantly after this point, the study hints that doctors might be able to switch strategies. Instead of using the heavy T-DXd missiles forever, they could switch to a lighter "maintenance" plan after about six cycles. This is like switching from a heavy-duty firehose to a gentle sprinkler once the fire is out. It keeps the situation stable without the extra wear and tear on the patient's body.
What the Study Rules Out
You might wonder if some patients need to keep the heavy missiles going longer than others. Maybe if the cancer is in the bones, or if the patient is older, or if they've had many other treatments before?
The study checked all these possibilities. They looked at patients with hormone-positive cancer versus hormone-negative cancer. They looked at patients who got T-DXd early in their treatment versus those who got it later (third line or later). They even checked if the cancer had spread to the brain, liver, or lungs.
The result? None of these factors changed the timing. Whether you are young or old, or whether the cancer is in the bones or the lungs, the "sweet spot" for maximum shrinking still lands right around 4.57 months. The study explicitly found no evidence that any specific group of people needs a different amount of time to reach their best result.
A Note on Confidence
It's important to remember that this is a look back at real-world data, not a brand-new, perfectly controlled experiment. The researchers are careful to say their findings suggest that the extra shrinking after 18 weeks is minimal. They didn't prove that every single person stops shrinking at exactly 4.57 months—some people's tumors kept shrinking a bit more, while others stopped sooner. But for the group as a whole, the data points clearly to that 4.57-month mark as the point of diminishing returns.
Also, the study didn't find any "magic bullet" factors that could predict exactly who would shrink faster or slower. It seems like the timing is a bit of a mystery that doesn't depend on the usual clues doctors look at.
The Bottom Line
In the world of fighting HER2-positive breast cancer, this study gives doctors a helpful map. It suggests that the heavy artillery of T-DXd does its best work in the first 4.57 months. After that, the city is as secure as it's going to get from that specific weapon, and it might be time to switch to a lighter, safer maintenance plan to keep the peace without overdoing it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.